Edwards starts trial for new BioPhysio heart valve:
This article was originally published in Clinica
Executive Summary
Edwards Lifesciences has begun a pivotal clinical trial of its next generation BioPhysio aortic valve, which it claims is the only replacement heart valve designed to mimic the physiologic motion of a natural heart valve. The valve combines the haemodynamic performance of a native valve with the ease of implant of a traditional stented valve, says the Irvine, California firm. The clinical trial is a large, multicentre study that will take place in Europe, Canada and the US. Enrolment is expected to last for around 18 months, followed by 12-18 months of post-procedural clinical monitoring and follow-up. Edwards hopes to start selling the device in Europe and Canada in 2008. US sales are expected to start later.
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.